Biegler has an average return of 150.7% when recommending Aptose Biosciences.
According to TipRanks.com, Biegler is ranked #441 out of 6214 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aptose Biosciences with a $11.17 average price target, representing a 47.9% upside. In a report issued on February 27, Canaccord Genuity also maintained a Buy rating on the stock with a $13.00 price target.
Based on Aptose Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $6.84 million. In comparison, last year the company had a GAAP net loss of $5.52 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent.